46
To boost the chances of recouping the cost of innovation bets, pharma companies must leverage a multi-pronged strategy that includes picking winning medicines, using technologies like AI and bringing the right external assets into the clinical fold.
Oncology has long been pharma’s biggest bucket for R&D, with investment historically leading to some of pharma’s most impactful breakthroughs. In the coming years, innovations such as radiopharmaceuticals, new immunotherapies, and next-generation cell and gene therapies offer cutting-edge solutions in cancer care.
included in this trendline
- Can China sustain a surge in oncology drug innovation?
- With ADCs on the rise, drugmakers embrace a new oncology pillar
- How leading oncology drugmakers set the stage for future advances
Offered Free by: PharmaVoice and Cencora
See All Resources from: PharmaVoice and Cencora